Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Bayer Pharma Aktiengesellschaft patents (2016 archive)


Recent patent applications related to Bayer Pharma Aktiengesellschaft. Bayer Pharma Aktiengesellschaft is listed as an Agent/Assignee. Note: Bayer Pharma Aktiengesellschaft may have other listings under different names/spellings. We're not affiliated with Bayer Pharma Aktiengesellschaft, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bayer Pharma Aktiengesellschaft-related inventors


Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

Polyethylene glycol based prodrug of adrenomedullin and use thereof

The invention relates to novel polyethylene glycol (peg) based prodrug of adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.. . ... Bayer Pharma Aktiengesellschaft

Aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides and use thereof

The present application relates to novel aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)

The present application relates to novel antibody drug conjugates (adcs), to active metabolites of these adcs, to processes for preparing these adcs, to the use of these adcs for the treatment and/or prophylaxis of diseases and to the use of these adcs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.. ... Bayer Pharma Aktiengesellschaft

Heteroaryl substituted pyrazoles

Compounds of formula (i), processes for their preparation and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

Determination of a time-dependent contrast agent injection curve as a function of ct scan parameters

A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. ... Bayer Pharma Aktiengesellschaft

Novel benzimidazole derivatives as ep4 ligands

The present invention relates to novel benzimidazole derivatives of the general formula (i), to processes for their preparation and to their use for preparing pharmaceutical compositions for the treatment of disorders and indications associated with the ep4 receptor.. . ... Bayer Pharma Aktiengesellschaft

Substituted piperidinyl-tetrahydroquinolines

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. . ... Bayer Pharma Aktiengesellschaft

Substituted bipiperidinyl derivatives

The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. . ... Bayer Pharma Aktiengesellschaft

Determining the velocity of a fluid using an imaging method

A method is described for determining the velocity of a fluid in a region to be investigated using an imaging method, preferably computer tomography, of an investigation object. In the method, a plurality of separately spaced sub regions of a region to be investigated, through which sub regions the fluid is flowing, are defined. ... Bayer Pharma Aktiengesellschaft

Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, copd and psoriasis.. . ... Bayer Pharma Aktiengesellschaft

Adenosine a1 agonists as medicaments for kidney disorders

The present application relates to selective partial adenosine a1 receptor agonists of the formula (i) and their use for treating and/or preventing diseases and to their use for preparing medicaments for treating and/or preventing diseases, preferably for treating and/or preventing acute and/or chronic kidney disorders (primary disorder and secondary disorder) with and without concomitant acute and/or chronic heart disorders.. . ... Bayer Pharma Aktiengesellschaft

Substituted bipiperidinyl derivatives

The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. . ... Bayer Pharma Aktiengesellschaft

10/20/16 / #20160304491

Substituted piperidinyltetrahydroquinolines

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. . ... Bayer Pharma Aktiengesellschaft

10/20/16 / #20160303136

Combination of pi3k-inhibitors

The present invention relates to combinations of at least two components, component a and component b, component a being an inhibitor of pi3k kinase, and component b being radium 223, particularly a pharmaceutically acceptable salt of radium-223. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer as well as their bone metatases.. ... Bayer Pharma Aktiengesellschaft

10/20/16 / #20160303134

Combination of pi3k-inhibitors

The present invention relates to combinations of at least two components, component a and component b, component a being an inhibitor of pi3k kinase, and component b being a pharmaceutically acceptable salt of radium 223. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of cancer with bone metatases.. ... Bayer Pharma Aktiengesellschaft

10/13/16 / #20160297833

Thienopyrimidines as mknk1 and mknk2 inhibitors

The present invention relates to substituted thienopyrimidine compounds of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

10/13/16 / #20160297811

Substituted triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (i); in which r1, r2, r3, r4, and r5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

10/13/16 / #20160297771

Substituted uracils and use thereof

The present application relates to novel substituted uracil derivatives of formula (i), to a method for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases, and to the use thereof for producing pharmaceuticals for the treatment and/or prevention of diseases.. . ... Bayer Pharma Aktiengesellschaft

10/13/16 / #20160296534

Progesterone receptor antagonist dosage form

The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.. ... Bayer Pharma Aktiengesellschaft

10/06/16 / #the present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (i) or (ib),

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

10/06/16 / #20160289220

Novel salts

Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid of the formula (i), in particular amino acid salts such as the lysine salt and alkali metal salts such as the sodium salt and the potassium salt, processes for their preparation, medicaments comprising them and their use for controlling diseases.. . ... Bayer Pharma Aktiengesellschaft

10/06/16 / #20160287599

Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors

Substituted 1,2,4-triazine-3,5-dione derivatives, processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

10/06/16 / #20160287589

Substituted-imidazopyridazines

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (i): (ia) (ib) (ic) (id) in which a, y, r1, r2, r3, r4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

09/29/16 / #20160280699

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

09/29/16 / #20160280688

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

09/22/16 / #the present invention relates to substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins, in particular brd4 proteins, and polo-like kinases, in particular plk-1 proteins of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

09/22/16 / #20160272637

Substituted oxopyridine derivatives

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

09/22/16 / #20160272617

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

09/15/16 / #20160264568

Substituted triazolopyridines having activity as mps-1 inhibitors

The present invention relates to substituted triazolopyridine compounds of general formula (i), in which r1, r2, r3, r4, and r5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

09/15/16 / #20160263122

Novel compounds

The present invention relates to substituted n-(phenyl-heteroaryl)-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: la represents an optionally substituted methylene or ethylene group; lb represents —n(h)—c(═0)- or —c(═0)—n(h)—; r1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —n(r7)(ci-c6-alkyl) group; r2 represents an optionally substituted 5- or 6-membered heteroaryl group; r3 represents an optionally substituted phenyl group.. . ... Bayer Pharma Aktiengesellschaft

09/08/16 / #20160256394

Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate

The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate (active ingredient (i)), characterized in that the active ingredient (i) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.. . ... Bayer Pharma Aktiengesellschaft

09/01/16 / #20160250349

A novel stable formulation

The present invention relates to a stable formulation particularly suitable for the anti-mesothelin immunoconjugate mf-t-spdb-dm4. The described stable aqueous formulation comprising mf-t-spdb-dm4 is directly suitable for therapeutic applications and for subsequent lyophilization. ... Bayer Pharma Aktiengesellschaft

08/25/16 / #20160244461

Cyclic thienouracil-carboxamides and use thereof

The present application relates to novel 2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide derivatives (“thienouracil”-carboxamides), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for the preparation of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

08/25/16 / #20160244437

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

08/25/16 / #20160244415

Substituted uracils as chymase inhibitors

Substituted uracil derivatives of formula (i), processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

08/18/16 / #20160237160

Anti-tweakr antibodies and uses thereof

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the tweakr (tnfrsf12a, fn14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the tweakr. ... Bayer Pharma Aktiengesellschaft

08/18/16 / #20160237067

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

08/18/16 / #20160237059

Heterocyclic substituted trifluoromethyl pyrimidinones and their use

The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3h)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.. . ... Bayer Pharma Aktiengesellschaft

08/18/16 / #20160237045

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

08/18/16 / #20160237044

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss. Trg416065. ... Bayer Pharma Aktiengesellschaft

08/04/16 / #20160222056

Substituted phenylalanine derivatives

The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.. . ... Bayer Pharma Aktiengesellschaft

08/04/16 / #20160221965

Disubstituted trifluoromethyl pyrimidinones and their use

The present application relates to novel 2,5-disubstituted 6-(trifluoromethyl)pyrimidin-4(3h)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.. . ... Bayer Pharma Aktiengesellschaft

08/04/16 / #20160220494

Pharmaceutical compositions containing refametinib

The present invention relates to pharmaceutical compositions which contain refametinib, a hydrate, solvate, meta bolite or pharmaceutically acceptable salt thereof or a polymorph thereof, and which are coated with a stability-maintaining coating, to processes of preparing such compositions, and to uses of such compositions for treating hyper-proliferative disorders and/or angiogenesis disorders, such as cancer, either as a sole agent or in combination with other anti-cancer therapies.. . ... Bayer Pharma Aktiengesellschaft

07/28/16 / #20160214977

Novel benzimidazole derivatives as ep4 antagonists

The present invention relates to novel benzimidazole derivatives of the general formula (i), processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor ep4.. . ... Bayer Pharma Aktiengesellschaft

07/21/16 / #20160207928

Novel compounds for the treatment of cancer

The present invention relates to novel compounds showing an inhibitory effect on mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

07/21/16 / #20160207915

Prodrug derivatives of substituted triazolopyridines

The present invention relates to prodrug derivatives of mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

07/07/16 / #the present invention relates to bet protein-inhibitory, especially brd4-inhibitory, dihydropyridopyrazinones of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

06/16/16 / #20160168130

Heteroaryl substituted pyrazoles

Compounds of formula (i), which are inhibitors of bub 1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

06/09/16 / #20160159816

Substituted thienopyrimidines and pharmaceutical use thereof

The present invention relates to substituted thienopyrimidine compounds of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

06/09/16 / #20160159789

Substituted pyrazolopyridines

The present invention relates to substituted pyrazolopyridine compounds of general formula i as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

06/02/16 / #20160152613

Substituted oxopyridine derivatives and use thereof as factor xia/plasma

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

06/02/16 / #20160151370

Substituted benzylpyrazoles

Compounds of formula (i) and their use as pharmaceutical.. . ... Bayer Pharma Aktiengesellschaft

05/26/16 / #20160145267

Heteroaryl substituted pyrazoles

Compounds of formula (i), which are inhibitors of bub1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

05/26/16 / #20160145239

Diaminoheteroaryl substituted pyrazoles

Compounds of formula (i), and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

05/26/16 / #20160145238

Heteroaryl substituted pyrazoles

Compounds of formula (i), which are inhibitors of bub1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

05/19/16 / #20160137647

Substituted benzoxazoles

The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.. . ... Bayer Pharma Aktiengesellschaft

05/12/16 / #bet-protein-inhibitory, in particular brd4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (i),

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

05/12/16 / #20160128988

Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

The present invention relates to a combination comprising an mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.. ... Bayer Pharma Aktiengesellschaft

05/05/16 / #20160122341

3-aryl-substituted imidazo[1,2-a]pyridines and their use

The present application relates to novel 3-aryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

05/05/16 / #20160122325

Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

The present invention relates to novel 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular and renal diseases.. . ... Bayer Pharma Aktiengesellschaft

04/07/16 / #20160096874

Mrg receptor modulators

The present invention is in the field of molecular biology, more particularly, the present invention relates to drug screening, assay development and identification and use of modulators for g-protein coupled receptor/ligand pair mrgx2/cxcl14 within drug discovery.. . ... Bayer Pharma Aktiengesellschaft

03/31/16 / #20160089364

Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception

The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2h-indazole as novel ep2 receptor antagonists in combination with cox inhibitors. ... Bayer Pharma Aktiengesellschaft

03/03/16 / #the present invention describes a new class of trinuclear hafnium complexes comprising two hexadentate azainositol carboxylic acid ligands, methods for their preparation and their use as x-ray contrast agents and x-ray diagnostic agents. the claimed compounds can be described by the following markush formula describing rinuclear hafnium complexes of general formula (i). the following is a compound according to the above markush formula (example 8).

Bayer Pharma Aktiengesellschaft üß

. . ... Bayer Pharma Aktiengesellschaft

03/03/16 / #20160058770

Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

—use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-hodgkin's lymphoma (nhl), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-hodgkin's lymphoma (nhl), in particular follicular lymphoma (fl), chronic lymphocytic leukaemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), transformed lymphoma (tl), or peripheral t-cell lymphoma (ptcl); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-hodgkin's lymphoma (nhl), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-hodgkin's lymphoma (nhl), in particular follicular lymphoma (fl), chronic lymphocytic leukaemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), transformed lymphoma (tl), or peripheral t-cell lymphoma (ptcl); —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of the expression of pi3k isoforms, btk and ikk, bcr activation, bcr downstream activation of nfkb pathway, c-myc, ezh2, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of the expression of pi3k isoforms, btk and ikk, bcr activation, bcr downstream activation of nfkb pathway, c-myc, ezh2.. . ... Bayer Pharma Aktiengesellschaft

02/25/16 / #20160052936

Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists

Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (gnrh) receptor antagonists.. ... Bayer Pharma Aktiengesellschaft

02/25/16 / #20160052898

Novel compounds

The present invention relates to substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

02/25/16 / #20160052884

Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

02/18/16 / #20160046610

3-heteroaryl substituted indazoles

Compounds of formula (i) which are inhibitors of bub1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

02/18/16 / #20160046604

Heteroaryl substituted indazoles

Compounds of formula (i), which are inhibitors of bub1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

02/18/16 / #20160045496

Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours

The invention relates to the use of (r)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide and/or (s)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for treating specific tumours.. . ... Bayer Pharma Aktiengesellschaft

01/28/16 / #20160024142

Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)

The invention relates to akr1c3 inhibitors of formula (i) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.. . ... Bayer Pharma Aktiengesellschaft

01/21/16 / #20160016959

Substituted imidazopyridazines

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

01/14/16 / #what is described are bet protein-inhibitory, especially brd2-, brd3- and brd4-inhibitory, bicyclo- and spino-substituted pyrrolo- and pyrazolodiazepines of the general formula i

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

01/14/16 / #20160009776

Pdgfrbeta-fc fusion proteins and uses thereof

The present disclosure provides pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of pdgfrbeta, or a biologically active fragment thereof, a linker and a fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The pdgfrbeta-fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g. ... Bayer Pharma Aktiengesellschaft

01/14/16 / #20160009734

Substituted thiazolopyrimidines

The present invention relates to substituted thiazolopyrimidine compounds of general formula i as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

01/14/16 / #20160008490

Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia

The present invention is directed to compounds that bind to glycoprotein iib/iiia and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein iib/iiia receptor combined with an adequate relaxivity.. ... Bayer Pharma Aktiengesellschaft

01/07/16 / #20160002267

Benzyl-substituted pyrazolopyridines and use thereof

The present application relates to novel benzyl-substituted pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

01/07/16 / #20160002245

Substituted pyrazolopyrimidinylamino-indazoles

The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of general formula i as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bayer Pharma Aktiengesellschaft in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bayer Pharma Aktiengesellschaft with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###